Bank of Montreal Can Has $356.18 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Bank of Montreal Can lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 684,661 shares of the medical research company’s stock after selling 84,016 shares during the period. Bank of Montreal Can’s holdings in Thermo Fisher Scientific were worth $356,181,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in TMO. Legacy Investment Solutions LLC acquired a new position in Thermo Fisher Scientific during the third quarter valued at approximately $26,000. Barrett & Company Inc. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $28,000. FPC Investment Advisory Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $28,000. Pillar Financial Advisors LLC acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at $29,000. Finally, Missouri Trust & Investment Co acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $29,000. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

TMO has been the subject of several research analyst reports. Wells Fargo & Company lifted their target price on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. UBS Group raised their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Morgan Stanley upped their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target on the stock in a report on Friday, January 10th. Finally, Bank of America lowered their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a report on Friday, December 13th. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $653.23.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $437.71 on Monday. The company’s fifty day moving average is $532.01 and its 200 day moving average is $547.03. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 52 week low of $411.12 and a 52 week high of $627.88. The stock has a market cap of $165.13 billion, a PE ratio of 26.48, a PEG ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.39%. Thermo Fisher Scientific’s dividend payout ratio is 10.41%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,900 shares of company stock valued at $13,106,062. Corporate insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.